Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Gilead to Introduce Blister-Pack Harvoni by Early March
February 2, 2017
- Over 80% of 5-Year-Olds Eligible for Supplemental Dose of Pneumococcal Vaccine: Pfizer Survey
February 2, 2017
- Daiichi Sankyo Taps EVP Manabe as Next President
February 1, 2017
- KHK7580 Non-Inferior to Regpara in Japan Study: Kyowa Kirin
February 1, 2017
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
- Daiichi Sankyo Sees High Odds of Success for CAR T-Cell Development: Exec
February 1, 2017
- Kyowa Kirin’s 2016 Sales, Profits Slip on Stronger Yen, Higher R&D Costs
February 1, 2017
- Kyowa Kirin, NCC to Collaborate on Cancer Meds, Biomarkers
February 1, 2017
- Takeda Obtains Japan Rights to Exelixis’ Cancer Drug
February 1, 2017
- Astellas Gets Rights to US Biotech’s Ruptured Eardrum Med
February 1, 2017
- Major Products Face Impending Listing of Generics, though Patents Remain for Some
February 1, 2017
- Biogen to Keep Its Focus on High Unmet Needs, Win-Win Partnerships: CEO
January 31, 2017
- Latuda OK’ed in US for Adolescent Schizophrenia
January 31, 2017
- Mochida Filed Enbrel Biosimilar in Japan in October-December
January 31, 2017
- Linzess Delivers Positive Japan PIII Data in Chronic Constipation: Astellas
January 31, 2017
- Nippon Chemiphar, Nagase Medicals Win Elplat Patent Suit
January 30, 2017
- Mitsubishi Tanabe, Biogen Terminate MS Licensing Deal
January 30, 2017
- SBI to Initiate UK PII Study of 5-ALA for Prevention of Postoperative Cardiac Output Reduction
January 30, 2017
- Shionogi to Seek Expansion of Pediatric Indication for Sublingual Allergen Immunotherapy Tablet Actair
January 30, 2017
- Chugai to Shuffle Sales Organization to Cater to Community-Based Care
January 27, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…